Acurx Pharmaceuticals, Inc. (ACXP) shareholders

ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.96−0.03 (-2.54%)

Close on Nov 13, 2026Market cap $5.06MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions

2.4%

0M of 5M shares

Institutional holders

2 new, 4 sold out

Net institutional buying

-0M

In Q2 2026

Insider trades, 12 months

0 buys · 0 sales

Open-market trades only

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

Holder	Shares	% of ACXP	Value	Change	% of portfolio
Vanguard Capital Management LLC	31,099	0.59%	$48.20K	–	0.00%
Geode Capital Management, LLC	26,411	0.50%	$40.94K	+1,592	0.00%
Vanguard Fiduciary Trust Co	16,205	0.31%	$25.12K	–	0.00%
Jane Street Group, LLC	15,727	0.30%	$24.38K	−38,915	0.00%
Prospect Financial Services LLC	13,785	0.26%	$21.37K	–	0.01%
Morgan Stanley	7,500	0.14%	$11.63K	+1,000	0.00%
Integrated Wealth Concepts LLC	4,729	0.09%	$7.33K	New	0.00%
Tower Research Capital LLC (TRC)	2,744	0.05%	$4.25K	+1,713	0.00%
Wells Fargo & Company/Mn	2,300	0.04%	$3.57K	–	0.00%
Westside Investment Management, Inc.	1,650	0.03%	$2.56K	–	0.00%
Nbc Securities, Inc.	1,500	0.03%	$2.33K	–	0.00%
Barclays PLC	281	0.01%	$436	−99	0.00%
Cornerstone Planning Group LLC	167	0.00%	$245	–	0.00%
Osaic Holdings, Inc.	100	0.00%	$155	–	0.00%
Group One Trading, L.P.	95	0.00%	$147	−150	0.00%
BlackRock, Inc.	60	0.00%	$93	–	0.00%
Caitong International Asset Management Co., Ltd	23	0.00%	$36	New	0.00%
SBI Securities Co., Ltd.	6	0.00%	$9	–	0.00%
UBS Group AG	3	0.00%	$5	−6,309	0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

Quarter	Holders	Shares held	% of shares	New / added	Reduced / closed	Shares bought	Shares sold
Q2 2026	19	0M	2.4%	2 / 3	4 / 4	0M	0M
Q1 2026	21	0M	3.5%	7 / 3	4 / 3	0M	0M
Q4 2025	18	0M	2.6%	7 / 3	5 / 5	0M	0M
Q3 2025	16	0M	1.1%	15 / 1	0 / 0	0M	0M
Q2 2025	1	0M	0.0%	1 / 0	0 / 0	0M	0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

5 funds held ACXP in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

Fund	Shares	% of ACXP	Value	% of fund	As of
Vanguard Extended Market Index Fund	31,099	0.59%	$48.20K	0.00%	Jun 30, 2026
Fidelity Extended Market Index Fund	16,250	0.31%	$32.18K	0.00%	May 31, 2026
Fidelity Series Total Market Index Fund	2,978	0.06%	$5.90K	0.00%	May 31, 2026
Fidelity Total Market Index Fund	1,001	0.02%	$1.98K	0.00%	May 31, 2026
Fidelity Nasdaq Composite Index Fund	146	0.00%	$289	0.00%	May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

Name	Role	Shares owned	% of shares	Latest filing
David P. Luci	President and CEO, Director	1,147,541	21.78%	Apr 22, 2026
Robert G. Shawah	Chief Financial Officer	189,200	3.59%	Apr 22, 2026
Carl Sailer	Director	142,183	2.70%	Apr 22, 2026
Jack H. Dean	Director	27,546	0.52%	Apr 22, 2026
James J. Donohue	Director	22,352	0.42%	Apr 22, 2026
Thomas L. Harrison	Director	1,539	0.03%	Apr 22, 2026
Robert J. Deluccia	Director	1,014,043	19.24%	Apr 22, 2026
Joseph C. Scodari	Director	27,708	0.53%	Apr 22, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

Insider	Date	Transaction	Shares	Price	Value	Shares after
Carl Sailer Director	Jan 6, 2025	Buy	+24,631	$1.02	$25.12K	137,183
Joseph C. Scodari Director	Jan 6, 2025	Buy	+24,631	$1.02	$25.12K	27,708
Robert J. Deluccia Director, 10% owner	Jan 6, 2025	Buy	+49,261	$1.02	$50.25K	1,010,196
Jack H. Dean Director	Jan 6, 2025	Buy	+9,852	$1.02	$10.05K	21,776
James J. Donohue Director	Jan 6, 2025	Buy	+9,852	$1.02	$10.05K	22,352
David P. Luci President and CEO, Director, 10% owner	Jan 6, 2025	Buy	+49,261	$1.02	$50.25K	1,097,458
Carl Sailer Director	Jan 19, 2024	Option exercise	+19,737	$3.55	$70.07K	112,552
David P. Luci President and CEO, Director, 10% owner	Jan 3, 2024	Option exercise	+19,737	$3.55	$70.07K	1,048,197
Robert J. Deluccia Director, 10% owner	Jan 3, 2024	Option exercise	+19,737	$3.55	$70.07K	960,935
Robert J. Deluccia Director, 10% owner	Dec 22, 2023	Gift	−30,000	–	–	941,198
Robert J. Deluccia Director, 10% owner	Dec 12, 2023	Gift	−40,000	–	–	971,198
Robert J. Deluccia Director, 10% owner	Jul 27, 2022	Buy	+19,737	$3.80	$75.00K	1,051,198
David P. Luci President and CEO, Director, 10% owner	Jul 27, 2022	Buy	+19,737	$3.80	$75.00K	1,028,460
Carl Sailer Director	Jul 27, 2022	Buy	+19,737	$3.80	$75.00K	92,815
Robert J. Deluccia Director, 10% owner	Dec 2, 2021	Gift	−40,000	–	–	1,011,198
Carl Sailer Director	Nov 23, 2021	Buy	+5,161	$4.84	$24.98K	73,078
Robert J. Deluccia Director, 10% owner	Nov 19, 2021	Buy	+5,034	$4.90	$24.67K	1,031,461
David P. Luci President and CEO, Director, 10% owner	Nov 19, 2021	Buy	+5,200	$4.80	$24.96K	1,008,723
Carl Sailer Director	Jun 29, 2021	Buy	+12,500	$6.00	$75.00K	67,917

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float

3.62%

0M shares short

Days to cover

1.6

At 0M shares a day

Change since last report

+7.5%

From 0M shares

Short volume, 20 days

41.9%

Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Acurx Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 15,738 shares on Aug 18, 2026 over the last 90 days.

See a number that looks wrong?